ROCHE SORIATANE LABELING SHOULD RETAIN THREE-YEAR POST-THERAPY CONTRACEPTION REQUIREMENT -- FDA ADVISORY CMTE.; TEGISON WILL BE REMOVED FROM MARKET

Roche's Soriatane (acitretin) labeling should continue to carry a boxed warning recommending three years of contraception against pregnancy in women of childbearing age following use of the psoriasis treatment, FDA's Dermatologic and Ophthalmic Drugs Advisory Committee concluded at its April 17 meeting.